top of page
The Professional Network for Healthcare Experts
Cipla licenses HER2 bispecific ADC TQB2102 from Sino Biopharmaceutical
The agreement gives Cipla exclusive rights to develop and commercialise the investigational HER2-targeted bispecific antibody-drug conjugate TQB2102 across India, South Africa and five additional emerging markets.
nuaxia
Sep 22 min read
AstraZeneca Licences Sino Biopharmaceutical’s TQC3721 Respiratory Drug in Potential $1.9bn Deal
The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China.
nuaxia
Jul 103 min read
bottom of page